Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
Recruiting
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/17/2025
Locations: University of Southern California, Los Angeles, California +14 locations
Conditions: Normal Pressure Hydrocephalus
Swallowing Impairments in Adults With and Without Alzheimer's Disease
Recruiting
This research study is investigating whether people with Alzheimer's disease (AD) experience more changes to swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe AD is high (85-93%), yet little is known about how swallow function evolves throughout the disease course in people with AD. The overall objective of this study is to evaluate swallowing function in adults with and without Alzheimer's disease. The investigator will also be involvin... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/17/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Alzheimer Disease, Caregiver Burden, Healthy Aging, Dysphagia
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Recruiting
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland +6 locations
Conditions: Carcinoma, Non-Small-Cell Lung
PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Recruiting
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain. These include headaches; loss of taste and smell; sleep problems; thinking problems; depression; and anxiety. Researchers want to know if a tracer (a substance that is injected into a person s body before an imaging scan) can help identify inflammation in people with these brain disorders. Objective: To see if a radioactive tracer (\[11C\]PS13) can hig... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Long COVID, Post Acute Sequelae of COVID-19
Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB)
Recruiting
This study is being done to test the feasibility and accuracy of using an ultrasound-guided core needle biopsy technique as a potential tool for staging urothelial carcinoma of the bladder (UCB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Bladder Urothelial Carcinoma
Natural History and Development of Spondyloarthritis
Recruiting
Background: - Spondyloarthritis (SpA) is a group of bone and joint disorders that may cause back and joint pain and stiffness. In some cases, SpA can lead to abnormal bone growth affecting the joints and spine. Some patients have SpA without ever developing these growths, while others develop them after only a few years. Researchers are interested in studying people with SpA and their relatives to determine which people are more likely to develop more severe conditions. Objectives: - To ident... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Arthritis, Spondylitis, Ankylosing
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +1146 locations
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Recruiting
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Alabama at Birmingham School of Medicine, Birmingham, Alabama +72 locations
Conditions: Candidiasis, Invasive, Candidemia
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +1027 locations
Conditions: Heart Failure
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/17/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +531 locations
Conditions: Progressive Pulmonary Fibrosis
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Recruiting
Background: As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose. Objective: To learn if UA improves levels of insulin and other hormones that help control blood glucose. Eligibility: People aged 55 years and older with a body mass index of 27 or higher.... Read More
Gender:
ALL
Ages:
Between 55 years and 100 years
Trial Updated:
06/17/2025
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Healthy Volunteer
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Recruiting
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in certain cancer cells. \[18F\]FAPI-74 is a new tracer-a substance that is injected into a person s body before an imaging scan. Researchers believe that \[18F\]FAPI-74 may be able to highlight FAP enzymes more effectively than approved tracers. If so, the new tracer would make it easier to find FAP-positive tumors in the body. Objective: To see if \[18F\]FAPI-74 PET scans are as good or better than oth... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma, Gastric Cancer, Bladder Cancer, Hepatocellular Carcinoma, Pheochromocytoma, Ovarian Cancer